ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer’s Disease

Clinical Diagnostics for Alzheimer’s Disease Expanded collaboration grants Alamar commercial rights to utilize ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests for clinical use  Expanded collaboration grants Alamar commercial rights to utilize ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests for clinical use  CARLSBAD, Calif., July 23, 2026 — ALZpath, Inc., a leader in blood test-based […]

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer’s Disease Testing

ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer’s Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 – ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath’s proprietary phosphorylated Tau 217 (pTau217) antibody […]